What is retatrutide?
What is Retatrutide? How does it affect
High-Purity Research Compounds | Trusted Quality & Consistency
High-Purity Research Compounds | Trusted Quality & Consistency
Last updated: May 21, 2026
Quick Answer
Retatrutide is a synthetic triple-receptor agonist targeting GLP-1, GIP, and glucagon pathways simultaneously, making it one of the most advanced incretin-based compounds currently under investigation. Researchers who want to buy retatrutide peptide for research can source it from qualified suppliers such as Sempica Healthcare, which provides independently verified, 99.8% purity lyophilised compounds for laboratory use. As of 2026, retatrutide remains an investigational compound — it is not FDA-approved and is not available as a standard prescription medicine [8].
Key Takeaways
Retatrutide is a synthetic 26-amino acid peptide designed to activate three distinct hormone receptor pathways: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple-agonist mechanism sets it apart from earlier incretin compounds, which target only one or two of these pathways.
Each receptor pathway contributes differently to metabolic regulation. GLP-1 receptor activation promotes insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite signalling in the hypothalamus. GIP receptor activation enhances insulin release and supports fat metabolism. Glucagon receptor activation increases energy expenditure and stimulates lipolysis. When all three are engaged simultaneously, the combined effect on metabolic function is substantially greater than what any single pathway can produce in isolation [2][9].
Retatrutide has an approximate half-life of 6 days, supporting once-weekly administration protocols in research models. It is produced as a lyophilised powder and reconstituted prior to use. Eli Lilly, the compound’s developer, describes it as an “investigational once-weekly triple hormone receptor agonist” that remains in active clinical development as of March 2026 [8].
Research-grade retatrutide is available from specialist scientific supply platforms for qualified laboratory professionals. The key distinction is between clinical access (restricted to approved trials) and research procurement (available through verified compound suppliers for preclinical and in vitro work).
For laboratory research, Sempica Healthcare supplies retatrutide in 20mg and 40mg formats, produced to a 99.8% purity standard and independently tested. All purchases are processed through a fully digital storefront with global shipping to 50+ countries. Sempica provides a Certificate of Analysis for every compound, ensuring full traceability.
When evaluating any supplier, researchers should confirm three things before placing an order: independent third-party purity testing, a current CoA available on request, and a clearly stated research-use-only policy. For broader guidance on sourcing compounds responsibly, Sempica’s guide to buying genuine peptides online for laboratory use covers the key criteria in detail.
Compliance note: Retatrutide cannot be legally prescribed, dispensed by a pharmacy, or sold as a therapeutic product outside of approved clinical trials [6]. Research procurement is a separate category governed by laboratory compliance protocols, not clinical prescribing frameworks.
Retatrutide occupies a distinct position among incretin-class research compounds because of its triple-receptor profile. Semaglutide is a single GLP-1 receptor agonist; tirzepatide is a dual GLP-1/GIP agonist. Retatrutide adds glucagon receptor agonism on top of both, which introduces a third mechanism — increased energy expenditure — that the other compounds do not provide.
| Compound | Receptor Targets | Half-Life | Research Applications |
|---|---|---|---|
| Semaglutide | GLP-1 | ~7 days | Metabolic, insulin resistance, appetite regulation |
| Tirzepatide | GLP-1 + GIP | ~5 days | Metabolic, body composition, cardiovascular |
| Retatrutide | GLP-1 + GIP + Glucagon | ~6 days | Advanced metabolic, energy expenditure, body composition |
Phase 2 trial data published in the NEJM showed retatrutide produced greater body weight reductions than those observed in comparable trials of tirzepatide and semaglutide, though direct head-to-head trial data is not yet available [2]. For researchers designing comparative metabolic studies, retatrutide is the logical third compound in a GLP-1 agonist series. Sempica’s GLP/GIP multi-pathway metabolic research peptides catalogue covers all three compounds and related incretin-class agents.
For researchers exploring adjacent metabolic pathways, MOTS-c (a mitochondrial-derived peptide acting on AMPK signalling) and tirzepatide are closely related comparators worth including in multi-compound research designs.
Yes — metabolic and body composition research is the primary application for retatrutide in preclinical and in vitro laboratory settings. The compound’s triple-agonist profile makes it particularly relevant for studies examining energy expenditure, lipolysis, insulin sensitivity, and appetite regulation.
Phase 2 data demonstrated that retatrutide produced dose-dependent reductions in body weight, with the highest dose group achieving approximately 17.5% mean weight reduction at 24 weeks [2]. A further study published via PMC confirmed significant improvements in metabolic markers including fasting glucose, lipid profiles, and waist circumference [1]. These findings make retatrutide a high-value compound for research teams investigating advanced metabolic models beyond what dual-agonist compounds can produce.
Researchers in this area should also consider reviewing Sempica’s metabolic and energy research compounds catalogue for complementary agents. For visceral fat-specific research models, tesamorelin offers a mechanistically distinct approach worth examining alongside incretin-class compounds.
Research-grade retatrutide pricing reflects the compound’s complexity, synthesis requirements, and purity verification costs. As a 26-amino acid peptide requiring precise acylation and independent quality testing, it is priced at a premium relative to simpler peptides.
Sempica offers retatrutide in two formats to suit different research scales:
Pricing is listed on the product pages and reflects the 99.8% purity standard and CoA inclusion. Researchers should factor in reconstitution consumables (bacteriostatic water, sterile syringes) and cold-chain storage requirements when budgeting for a research protocol. Bulk or institutional ordering enquiries can be directed to Sempica’s contact team.
Lyophilised retatrutide powder must be stored at -20°C, away from light and moisture, until ready for use. Under these conditions, the compound remains stable until its labelled expiry date. Once reconstituted, the solution should be kept at 2–8°C (refrigerator temperature) and used within the timeframe specified by the supplier.
Key storage rules for research professionals:
For a full protocol reference, Sempica’s laboratory guide on how to mix and store peptides covers reconstitution procedures, concentration calculations, and storage best practices in detail.
Retatrutide research compounds are sold exclusively to qualified research professionals. Sempica requires purchasers to confirm they are qualified professionals who will use compounds strictly for laboratory research — not for human consumption, self-administration, or therapeutic purposes.
In practice, this means:
There is no requirement for a medical licence or clinical prescribing authority — research compound procurement operates under laboratory supply frameworks, not pharmaceutical dispensing regulations. However, researchers should confirm their institution’s internal compliance requirements before ordering, as some organisations have internal approval processes for novel investigational compounds.
In preclinical research settings, retatrutide’s known pharmacological profile includes gastrointestinal effects (nausea, reduced appetite, altered gastric motility) observed in animal models and Phase 2 trial participants [2]. Researchers designing in vivo protocols should account for these effects when establishing baseline parameters and monitoring endpoints.
From a laboratory handling perspective, the risks are consistent with other synthetic peptides:
Mabry Medical notes that research-grade compounds of this class are “not legally approved for human use outside of approved studies” and carry risks when used outside controlled research settings [4]. All handling should follow institutional biosafety protocols. Researchers should review the compound’s current safety data and consult their institution’s research ethics and compliance office before initiating in vivo work.
For credible research outcomes, retatrutide should meet a minimum purity standard of 99% or higher. Lower-purity compounds introduce contaminants that can confound experimental results, particularly in sensitive metabolic or receptor-binding assays.
Sempica’s compounds are produced and independently tested to a 99.8% purity standard, with a Certificate of Analysis available for every product. A CoA should confirm identity (correct amino acid sequence), purity (HPLC verification), and potency. Researchers should request the CoA before or at the time of purchase and verify that testing was performed by an independent third-party laboratory — not the supplier’s own internal testing facility.
Decision rule: If a supplier cannot provide an independent CoA on request, do not purchase. Purity claims without third-party verification are not sufficient for research-grade procurement.
Several compounds serve as mechanistic comparators or alternatives depending on the specific research question.
Direct comparators (incretin class):
Adjacent metabolic compounds:
The choice between these compounds depends on the research question. Choose retatrutide if the study requires glucagon receptor activation as a distinct variable. Choose tirzepatide if the research focuses on dual incretin effects without the glucagon component. Choose semaglutide as the single-agonist control in a receptor-pathway series.
Retatrutide is used primarily by academic research laboratories, pharmaceutical research organisations, and independent research groups investigating metabolic disease, obesity biology, and energy homeostasis. Given its Phase 2 clinical trial profile and the intensity of scientific interest in triple-agonist compounds, it is most common in:
The compound’s investigational status and the volume of published Phase 2 data [2][1] have made it a priority compound for any institution with an active metabolic research programme in 2026.
Even experienced laboratory professionals make avoidable errors with complex synthetic peptides. The most common issues with retatrutide specifically include:
Q: Is retatrutide approved for human use in 2026? No. As of 2026, retatrutide remains an investigational compound. It is not FDA-approved and cannot be legally prescribed or dispensed outside of approved clinical trials [8][6].
Q: What is the difference between research-grade and clinical-grade retatrutide? Research-grade retatrutide is produced for laboratory use in preclinical and in vitro settings. Clinical-grade compounds used in approved trials are manufactured under GMP conditions and subject to regulatory oversight. Research-grade compounds are not approved for human administration.
Q: What purity standard should research-grade retatrutide meet? A minimum of 99% purity is the accepted standard for credible research. Sempica’s compounds are tested to 99.8% purity with independent CoA verification.
Q: How should retatrutide be reconstituted? Add bacteriostatic water slowly down the inside wall of the lyophilised vial. Gently swirl until fully dissolved. Do not shake or vortex. Label with the reconstitution date and store at 2–8°C.
Q: Can retatrutide be used in in vitro cell culture studies? Yes. In vitro studies examining GLP-1, GIP, and glucagon receptor binding, signalling pathway activation, and cellular metabolic responses are all established applications for research-grade retatrutide.
Q: Does Sempica ship retatrutide internationally? Yes. Sempica ships to 50+ countries worldwide. All orders are processed through the digital storefront at sempicahealthcare.ch with secure, direct-to-door delivery.
Q: What is a Certificate of Analysis and why does it matter? A CoA is a document from an independent testing laboratory confirming a compound’s identity, purity, and potency. It is the primary quality assurance document for research procurement and should be requested before purchase.
Q: How long does reconstituted retatrutide remain stable? When reconstituted with bacteriostatic water and stored at 2–8°C, the solution is stable for up to 28 days. Never freeze a reconstituted solution.
Q: What receptor does retatrutide activate that tirzepatide does not? Retatrutide activates the glucagon receptor in addition to GLP-1 and GIP receptors. Tirzepatide activates only GLP-1 and GIP receptors. This glucagon component drives additional energy expenditure and lipolysis effects in research models [2][9].
Q: Are there combination products that include retatrutide? Yes. Sempica offers CagriReta, a pre-formulated combination of cagrilintide and retatrutide, designed for multi-pathway metabolic research protocols.
For research professionals investigating metabolic pathways, body composition mechanisms, or energy expenditure biology, retatrutide represents the most pharmacologically advanced incretin-class compound currently available for laboratory study. Its triple-agonist profile — spanning GLP-1, GIP, and glucagon receptors — produces a mechanistically distinct research model that neither semaglutide nor tirzepatide can replicate.
Actionable next steps for research teams:
Retatrutide’s Phase 2 results have generated significant scientific interest [2][1], and the compound is likely to remain a priority research agent throughout 2026 and beyond. Researchers who want to buy retatrutide peptide for research should prioritise purity, provenance, and protocol rigour above all else.
Mandatory Disclaimer: Products sold on this website are intended for research purposes only. They are not for human consumption, medical use, or therapeutic application. By purchasing from this website, you confirm that you are a qualified professional and will use these products strictly for laboratory research.
[1] Pmc12026077 – https://pmc.ncbi.nlm.nih.gov/articles/PMC12026077/ [2] Nejmoa2301972 – https://www.nejm.org/doi/full/10.1056/NEJMoa2301972 [4] The Promise And Caution Of Retatrutide Understanding Research Grade Medications For Patients – https://www.mabrymedical.com/post/the-promise-and-caution-of-retatrutide-understanding-research-grade-medications-for-patients [6] How To Get Retatrutide – https://www.joinmidi.com/post/how-to-get-retatrutide [8] What To Know About Retatrutide – https://www.lilly.com/news/stories/what-to-know-about-retatrutide [9] Retatrutide And The Rise Of The Triple G – https://peptideresearch.us/retatrutide-and-the-rise-of-the-triple-g/
What is Retatrutide? How does it affect
What is tirzepatide mechanism of action for
Buy Retatrutide Peptide for weight loss Last